Carlson brings a breadth of healthcare business development and leadership experience to MedicaMetrix
BOSTON, MASSACHUSETTS, June 1, 2020 (GLOBE NEWSWIRE) – MedicaMetrix, LLC, a leader in developing and marketing innovative medical devices and healthcare
solutions, today announced the appointment of Richard C. Carlson as EVP of Global Business Development effective June 1, 2020.
Richard C. Carlson brings more than 20 years of prostate disease market experience and has been involved in companies focused on the specialty of urology for more than 30 years. Carlson has a proven leadership track record in the US, Europe and other global markets and is responsible for scaling MedicaMetrix rapidly in both the US and international markets. Throughout all of his previous positions, Carlson has developed relationships with key urologists and other physicians in major medical centers throughout the U.S., Europe and Japan. Prior to MedicaMetrix, Carlson served as the CEO of ProUroCare Medical, Inc., a developer of a mechanical imaging device that creates a real-time color image of the prostate.
Carlson currently is serving as the Director of Business Development for a company with an innovative product and technology for eliminating biofilm and other bacteria in water-based facilities. Carlson developed their U.S. and international dealer network which resulted in a 65% increase in sales (yoy) in 2019.
Earlier in his career, Carlson identified clinical and economic benefits of a range of medtech devices and products, developed requirements for obtaining clinical validation and regulatory approvals in the US and Europe. He also designed training materials and scalable in-service training programs for physicians, and developed product, clinical, regulatory and commercialization strategies for marketing the products.
Carlson has created unique medtech device business models, reimbursement strategy, billing models to maximize revenue, acquired and helped submit more than 20 patents to provide a strong intellectual property position. He also helped four medical device companies develop go-to-market strategies and channel and distribution strategies.
Carlson’s previous urology work experience in the medical device industry includes industry leaders such as American Medical Systems, C. R. Bard, Boston Scientific and
Advanced Surgical Intervention, Medtronic and Vicon Systems.
“Rick brings a wealth of experience to MedicaMetrix as we begin to build our global marketing and distribution networks,” stated Robert Rudelius, President and CEO of MedicaMetrix. “Rick’s unique expertise will allow us to strengthen our relationships with key stakeholders, including clinicians, leading healthcare institutions, distribution partners and payors, which will be invaluable as MedicaMetrix seeks to build and lead our target markets.”
MedicaMetrix develops innovative technologies and device solutions that transform the healthcare status quo, leading to better medical outcomes, streamlined care and enhanced patient experience.
We are leading the development of a new paradigm that transforms the diagnosis, treatment, and management of prostate health by filling the gap between PSA testing and imaging / biopsies. The ProstaMetrix system is a minimally invasive medical device designed to accurately measure the volume of the prostate gland early in the diagnostic process. ProstaMetrix helps physicians assess a patient’s prostate status to better plan and monitor diagnostic procedures, treatments, drug therapies, and guide recommendations for active surveillance versus prostate biopsies.
MedicaMetrix is planning to acquire and develop other new medical devices with the goal to bring them to market rapidly by leveraging our planned production facilities in the U.S. and India.
Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events, or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forwardlooking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.